Sasaki, Tetsuya
Kato, Yasuhisa
Sato, Atsushi
Usui, Noriko
Baba, Eishi
Takano, Toshimi
Susumu, Nobuyuki
Ohnishi, Kazunori
Nishimoto, Hitomi
Kiura, Katsuyuki
Article History
Received: 4 October 2017
Accepted: 9 January 2018
First Online: 17 January 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: TS, NS, KO, and HN have no conflict of interest. YK has an advisory role at Yakult Honsha. AS has received honoraria from Chugai Pharmaceutical. NU has received honoraria from Kyowa Hakko Kirin, Chugai Pharmaceutical, and Mochida Pharmaceutical. EB has received honoraria from Eli Lilly and has research funding from Eli Lilly and Takeda Pharmaceutical. TT has received honoraria from Daiichi Sankyo and Kyowa Hakko Kirin and research funding from Chugai Pharmaceutical, Takeda Pharmaceutical, Taiho Pharmaceutical, Novartis Pharma, Ono Pharmaceutical, and MSD. KK has received honoraria from Chugai Pharmaceutical, Pfizer, Novartis Pharma, Taiho Pharmaceutical, and Eli Lilly and has research funding from Boehringer Ingerheim, Nippon Kayaku, Daiichi Sankyo, Shionogi, and Ono Pharmaceutical.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.